• Gene fusion; HGNC; HGNC:3689; FGFR2 + HGNC; HGNC:8124; OGDH; Name(s)=FGFR2-OGDH; Note=In frame (PubMed=26680454; PubMed=30737244).
  
• Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Gln70Serfs*102 (c.207delG) (G55fs); Zygosity=Homozygous (PubMed=26680454; PubMed=30737244).
  
• Mutation; HGNC; HGNC:18128; HDAC10; Simple; p.His134Thrfs*19 (c.399delG); dbSNP=rs759210981; Zygosity=Heterozygous (PubMed=26680454).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Homozygous (PubMed=30737244).
  

PubMed=20810568; DOI=10.1210/jc.2010-1421; PMCID=PMC2999968
Marlow L.A., D'Innocenzi J., Zhang Y.-L., Rohl S.D., Cooper S.J., Sebo T.J., Grant C., McIver B., Kasperbauer J.L., Wadsworth J.T., Casler J.D., Kennedy P.W., Highsmith W.E. Jr., Clark O., Milosevic D., Netzel B.C., Cradic K.W., Arora S., Beaudry C., Grebe S.K.G., Silverberg M.L., Azorsa D.O., Smallridge R.C., Copland J.A. 3rd
Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.
J. Clin. Endocrinol. Metab. 95:5338-5347(2010)

PubMed=23724124; DOI=10.1371/journal.pone.0065095; PMCID=PMC3665717
Li W., Reeb A.N., Sewell W.A., Elhomsy G., Lin R.-Y.
Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells.
PLoS ONE 8:E65095-E65095(2013)

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25675381; DOI=10.1210/jc.2014-2764; PMCID=PMC4422887
von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J., Tun H.W., Smallridge R.C., Copland J.A. 3rd
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
J. Clin. Endocrinol. Metab. 100:E697-E709(2015)

PubMed=26680454; DOI=10.1186/s12885-015-1955-9; PMCID=PMC4683857
Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J., Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.
The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
BMC Cancer 15:984.1-984.11(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)